,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,1 Controls Drive,Shelton,CT,06484,United States,203 937 6137,203 859 5095,https://www.nanoviricides.com,Biotechnology,Healthcare,"NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.",17,"{'maxAge': 1, 'name': 'Dr. Anil R. Diwan Ph.D.', 'age': 63, 'title': 'Exec. Chairman, Pres, CEO & Sec.', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 400000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.33,1.34,1.26,1.34,1.33,1.34,1.26,1.34,0.0,1.173928,-1.8529412,18408,18408,106085,22790,22790,1.26,1.28,1000,1000,14740110,1.04,2.0,1.4466,1.3304,0.0,0.0,USD,5048699,0.0,11156662,11698500,494387,486922,1690761600,1693440000,0.0423,0.04379,0.1074,12.03,0.0446,1.562,0.8066581,1656547200,1688083200,1680220800,-6798577,-0.56,-0.68,1:20,1569283200,-0.8,ASE,EQUITY,NNVC,NNVC,"NanoViricides, Inc.","NanoViricides, Inc.",1130333400,America/New_York,EDT,-14400000,1.26,2.0,buy,9650958,0.827,-6313275,0,27.673,28.477,-0.20184,-0.31632,-3400159,-5569171,0.0,0.0,0.0,USD,
1,1 Controls Drive,Shelton,CT,06484,United States,203 937 6137,203 859 5095,https://www.nanoviricides.com,Biotechnology,Healthcare,"NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.",17,"{'maxAge': 1, 'name': 'Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA', 'age': 63, 'title': 'Chief Financial Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 129600, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.33,1.34,1.26,1.34,1.33,1.34,1.26,1.34,0.0,1.173928,-1.8529412,18408,18408,106085,22790,22790,1.26,1.28,1000,1000,14740110,1.04,2.0,1.4466,1.3304,0.0,0.0,USD,5048699,0.0,11156662,11698500,494387,486922,1690761600,1693440000,0.0423,0.04379,0.1074,12.03,0.0446,1.562,0.8066581,1656547200,1688083200,1680220800,-6798577,-0.56,-0.68,1:20,1569283200,-0.8,ASE,EQUITY,NNVC,NNVC,"NanoViricides, Inc.","NanoViricides, Inc.",1130333400,America/New_York,EDT,-14400000,1.26,2.0,buy,9650958,0.827,-6313275,0,27.673,28.477,-0.20184,-0.31632,-3400159,-5569171,0.0,0.0,0.0,USD,
2,1 Controls Drive,Shelton,CT,06484,United States,203 937 6137,203 859 5095,https://www.nanoviricides.com,Biotechnology,Healthcare,"NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.",17,"{'maxAge': 1, 'name': 'Dr. Randall W. Barton Ph.D.', 'age': 75, 'title': 'Chief Scientific Officer & Chief Regulatory Officer', 'yearBorn': 1947, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.33,1.34,1.26,1.34,1.33,1.34,1.26,1.34,0.0,1.173928,-1.8529412,18408,18408,106085,22790,22790,1.26,1.28,1000,1000,14740110,1.04,2.0,1.4466,1.3304,0.0,0.0,USD,5048699,0.0,11156662,11698500,494387,486922,1690761600,1693440000,0.0423,0.04379,0.1074,12.03,0.0446,1.562,0.8066581,1656547200,1688083200,1680220800,-6798577,-0.56,-0.68,1:20,1569283200,-0.8,ASE,EQUITY,NNVC,NNVC,"NanoViricides, Inc.","NanoViricides, Inc.",1130333400,America/New_York,EDT,-14400000,1.26,2.0,buy,9650958,0.827,-6313275,0,27.673,28.477,-0.20184,-0.31632,-3400159,-5569171,0.0,0.0,0.0,USD,
